SCHEMBL5387637

SCHEMBL5387637

Cc1ccc(Nc2n[nH]c(SCc3ccc(C)s3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 10/20 0.43
RAB9A P51151 6/20 0.40
NPC1 O15118 5/20 0.40
MAPT P10636 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
CASP3 P42574 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
GAA P10253 2/20 0.37
ALDH1A1 P00352 1/20 0.36
LMNA P02545 2/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5384649 0.91 CDK2 (0.40) METAP2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL5372105 0.90 SMN1; SMN2 (0.43) METAP2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL5380332 0.88 METAP2 (0.42) METAP2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL5385647 0.88 METAP2 (0.42) METAP2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL5377014 0.86 NFKB1 (0.40) RAB9ANPC1MAPTSMN1; SMN2MEN1
SCHEMBL5377242 0.82 METAP2 (0.65) METAP2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL5381901 0.81 METAP2 (0.42) METAP2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL7083924 0.80 MAPT (0.44) METAP2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL5371964 0.79 METAP2 (0.62) METAP2RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL5374255 0.78 METAP2 (0.41) METAP2RAB9ANPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304082-B2 1,2,4-triazole derivatives, compositions, process of making and methods of use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-04 US disclosed
US-20050267185-A1 1,2,4-triazole derivatives, compositions, process of making and methods of use SMITHKLINE BEECHAM CORPORATION 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267185-A1 1,2,4-triazole derivatives, compositions, process of making and methods of use METAP2, METAP1, DNPEP METAP2 1/4885RAB9A 2324/4885NPC1 4364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.